FOXO1i (AS1842856) is emerging as a selective chemotherapeutic drug against FOXO1 which is currently used for the treatment of Type II diabetic mullites (T2DM) [36,37]. The gene discussed is FOXO1; the disease is type 2 diabetes mellitus.